Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Late intervention with anti-BRAF(V600E) therapy induces tumor regression in an orthotopic mouse model of human anaplastic thyroid cancer.

Nehs MA, Nucera C, Nagarkatti SS, Sadow PM, Morales-Garcia D, Hodin RA, Parangi S.

Endocrinology. 2012 Feb;153(2):985-94. doi: 10.1210/en.2011-1519. Epub 2011 Dec 27.

2.

Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer.

Nucera C, Nehs MA, Nagarkatti SS, Sadow PM, Mekel M, Fischer AH, Lin PS, Bollag GE, Lawler J, Hodin RA, Parangi S.

Oncologist. 2011;16(3):296-309. doi: 10.1634/theoncologist.2010-0317. Epub 2011 Feb 25.

3.

Thyroidectomy with neoadjuvant PLX4720 extends survival and decreases tumor burden in an orthotopic mouse model of anaplastic thyroid cancer.

Nehs MA, Nagarkatti S, Nucera C, Hodin RA, Parangi S.

Surgery. 2010 Dec;148(6):1154-62; discussion 1162. doi: 10.1016/j.surg.2010.09.001.

4.
5.

B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression.

Nucera C, Porrello A, Antonello ZA, Mekel M, Nehs MA, Giordano TJ, Gerald D, Benjamin LE, Priolo C, Puxeddu E, Finn S, Jarzab B, Hodin RA, Pontecorvi A, Nose V, Lawler J, Parangi S.

Proc Natl Acad Sci U S A. 2010 Jun 8;107(23):10649-54. doi: 10.1073/pnas.1004934107. Epub 2010 May 24.

6.

p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer.

McFadden DG, Vernon A, Santiago PM, Martinez-McFaline R, Bhutkar A, Crowley DM, McMahon M, Sadow PM, Jacks T.

Proc Natl Acad Sci U S A. 2014 Apr 22;111(16):E1600-9. doi: 10.1073/pnas.1404357111. Epub 2014 Apr 7.

7.

TSH overcomes Braf(V600E)-induced senescence to promote tumor progression via downregulation of p53 expression in papillary thyroid cancer.

Zou M, Baitei EY, Al-Rijjal RA, Parhar RS, Al-Mohanna FA, Kimura S, Pritchard C, Binessa HA, Alzahrani AS, Al-Khalaf HH, Hawwari A, Akhtar M, Assiri AM, Meyer BF, Shi Y.

Oncogene. 2016 Apr 14;35(15):1909-18. doi: 10.1038/onc.2015.253. Epub 2015 Oct 19.

PMID:
26477313
8.

Expression of angiogenic switch, cachexia and inflammation factors at the crossroad in undifferentiated thyroid carcinoma with BRAF(V600E).

Husain A, Hu N, Sadow PM, Nucera C.

Cancer Lett. 2016 Oct 1;380(2):577-85. doi: 10.1016/j.canlet.2015.07.012. Epub 2015 Jul 17.

9.
10.

An in vivo mouse model of metastatic human thyroid cancer.

Zhang L, Gaskins K, Yu Z, Xiong Y, Merino MJ, Kebebew E.

Thyroid. 2014 Apr;24(4):695-704. doi: 10.1089/thy.2013.0149. Epub 2014 Mar 10.

11.

Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer.

Brauner E, Gunda V, Vanden Borre P, Zurakowski D, Kim YS, Dennett KV, Amin S, Freeman GJ, Parangi S.

Oncotarget. 2016 Mar 29;7(13):17194-211. doi: 10.18632/oncotarget.7839.

12.

Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation.

Chakravarty D, Santos E, Ryder M, Knauf JA, Liao XH, West BL, Bollag G, Kolesnick R, Thin TH, Rosen N, Zanzonico P, Larson SM, Refetoff S, Ghossein R, Fagin JA.

J Clin Invest. 2011 Dec;121(12):4700-11. doi: 10.1172/JCI46382. Epub 2011 Nov 21.

13.

Blocks to thyroid cancer cell apoptosis can be overcome by inhibition of the MAPK and PI3K/AKT pathways.

Gunda V, Bucur O, Varnau J, Vanden Borre P, Bernasconi MJ, Khosravi-Far R, Parangi S.

Cell Death Dis. 2014 Mar 6;5:e1104. doi: 10.1038/cddis.2014.78.

14.

BRAF V600E inhibition in anaplastic thyroid cancer.

Rosove MH, Peddi PF, Glaspy JA.

N Engl J Med. 2013 Feb 14;368(7):684-5. doi: 10.1056/NEJMc1215697. No abstract available.

15.

Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells.

Salerno P, De Falco V, Tamburrino A, Nappi TC, Vecchio G, Schweppe RE, Bollag G, Santoro M, Salvatore G.

J Clin Endocrinol Metab. 2010 Jan;95(1):450-5. doi: 10.1210/jc.2009-0373. Epub 2009 Oct 30.

PMID:
19880792
16.

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.

Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, Bremer R, Gillette S, Kong J, Haass NK, Sproesser K, Li L, Smalley KS, Fong D, Zhu YL, Marimuthu A, Nguyen H, Lam B, Liu J, Cheung I, Rice J, Suzuki Y, Luu C, Settachatgul C, Shellooe R, Cantwell J, Kim SH, Schlessinger J, Zhang KY, West BL, Powell B, Habets G, Zhang C, Ibrahim PN, Hirth P, Artis DR, Herlyn M, Bollag G.

Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3041-6. doi: 10.1073/pnas.0711741105. Epub 2008 Feb 19.

17.

Cyp24a1 Attenuation Limits Progression of BrafV600E -Induced Papillary Thyroid Cancer Cells and Sensitizes Them to BRAFV600E Inhibitor PLX4720.

Zou M, Baitei EY, BinEssa HA, Al-Mohanna FA, Parhar RS, St-Arnaud R, Kimura S, Pritchard C, Alzahrani AS, Assiri AM, Meyer BF, Shi Y.

Cancer Res. 2017 Apr 15;77(8):2161-2172. doi: 10.1158/0008-5472.CAN-16-2066. Epub 2017 Feb 27.

PMID:
28242615
18.

CLM29 and CLM24, pyrazolopyrimidine derivatives, have antitumoral activity in vitro in anaplastic thyroid cancer, with or without BRAF mutation.

Fallahi P, Ferrari SM, La Motta C, Materazzi G, Bocci G, Da Settimo F, Miccoli P, Antonelli A.

Endocrine. 2016 Jul;53(1):136-44. doi: 10.1007/s12020-015-0717-4. Epub 2015 Aug 19.

PMID:
26286966
19.

The next generation of orthotopic thyroid cancer models: immunocompetent orthotopic mouse models of BRAF V600E-positive papillary and anaplastic thyroid carcinoma.

Vanden Borre P, McFadden DG, Gunda V, Sadow PM, Varmeh S, Bernasconi M, Jacks T, Parangi S.

Thyroid. 2014 Apr;24(4):705-14. doi: 10.1089/thy.2013.0483. Epub 2014 Jan 24.

20.

Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma.

Dasgupta T, Olow AK, Yang X, Hashizume R, Nicolaides TP, Tom M, Aoki Y, Berger MS, Weiss WA, Stalpers LJ, Prados M, James CD, Mueller S, Haas-Kogan DA.

J Neurooncol. 2016 Feb;126(3):385-93. doi: 10.1007/s11060-015-1939-2. Epub 2015 Sep 18. Erratum in: J Neurooncol. 2016 Feb;126(3):395.

Supplemental Content

Support Center